Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication
Category: dates
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
20210121 TG4050 1st patient HNSCC EN
Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
20210119 – ANSM Approval BT-001 EN
Transgene Appoints Gaëlle Stadtler as Director of Human Resources
20210114 Transgene – Appointment Gaelle Stadtler_EN
Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
20201221 – CTA Approval BT-001 – EN
Transgene Announces Financial Calendar for 2021
20191217 Financial calendar 2021 EN
Transgene Announces Investor Meetings for January 2021
20201216 PR Investors Meeting agenda Jan 2021
Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
20201203 – TG4001 mini oral prez ESMO IO EN
Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
20201203 – Nomination Transgene – EN
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication